Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT02284139 Completed - Colorectal Cancer Clinical Trials

Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects

Start date: April 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The efficacy of the epidermal growth factor receptor (EGFR) inhibitors have been demonstrated in patients with non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and colorectal cancer (CRC). Dermatological reactions can cause significant physical and psycho-social discomfort to patients. In the present study, the investigators evaluated the effect of epidermal growth factor (EGF) ointment on EGFR inhibitor-related skin side effects (ERSEs).

NCT ID: NCT02283372 Completed - Pancreatic Cancer Clinical Trials

Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer

Start date: January 21, 2015
Phase: Phase 1
Study type: Interventional

A phase I study to evaluate safety of gemcitabine with nab-paclitaxel and concurrent IMRT for locally advanced and borderline resectable pancreatic cancer. The goal of this study is to evaluate if a chemotherapy regimen that provides superior systemic efficacy may be safely delivered and enhance efficacy of tumor directed radiation therapy.

NCT ID: NCT02282722 Completed - Clinical trials for Metastatic Colorectal Cancer

Improving Informed Consent for Palliative Chemotherapy

Start date: June 10, 2015
Phase: N/A
Study type: Interventional

Patients are routinely asked to sign an "informed consent" document prior to starting chemotherapy, indicating they understand the risks and benefits of treatment. Although this could be a strategic moment to equip patients with information they need to make truly informed medical decisions, many patients and caregivers note that these conversations are less useful than they could be. The informed consent process and its associated documents suffer several limitations: 1) risks are emphasized over benefits; 2) educational materials focus on individual drugs instead of regimens; 3) information is presented in written instead of alternative written/audiovisual format; and 4) the patient perspective is lacking. The overarching objective of this project is to develop a library of communication tools for the most common chemotherapy regimens used to treat advanced gastrointestinal cancers. Tools will include video clips and written documents that can be readily distributed, modified, and customized. This toolkit will be crafted in collaboration with oncologists and patients living with gastrointestinal cancer and improves upon existing resources in several ways: 1) balanced discussion of benefits as well as risks, 2) focus on regimens rather than drugs, 3) use of both written and video format, and 4) inclusion of the patient perspective (e.g. video clips of patients describing their experience). A panel of oncologist and patient stakeholders will evaluate the acceptability of the tools. The investigators will then conduct a randomized clinical trial to demonstrate if the informed consent toolkit improves the quality of informed consent for palliative chemotherapy. If effective, the tools will be amenable to broad dissemination via patient accessible cancer education websites and oncology clinics.

NCT ID: NCT02277834 Completed - Pancreatic Cancer Clinical Trials

Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice

Start date: August 2014
Phase: N/A
Study type: Observational

Currently, X-rays and blood tests often miss pancreatic cancer. In this study, we are collecting and studying the fluid produced by the pancreas as a way to detect pancreatic cancer at an earlier stage.

NCT ID: NCT02272738 Completed - Pancreatic Cancer Clinical Trials

A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer

Start date: August 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the clinical safety and efficacy of Gemcitabine plus nab-Paclitaxel chemoradiotherapy and to determine the Maximal Tolerated Dose (MTD) for unresectable locally advanced pancreatic adenocarcinoma.

NCT ID: NCT02270554 Completed - Clinical trials for Pancreatic Neoplasms

A Prospective, Multi-center Trial for Reinforced Staple During Distal Pancreatectomy

Start date: October 2014
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate if the Endo GIA Reinforced Reload with Tri-Staple Technology reduce incidence of pancreatic fistula (ISGPF grade B and C) after distal pancreatectomy by a prospective, multi-center trial.

NCT ID: NCT02261714 Completed - Clinical trials for Pancreatic Cancer, Resected

Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

Start date: December 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the effect of TG01 and Granulocyte macrophage colony stimulating factor (GM-CSF) when given in addition to gemcitabine (chemotherapy) and - Understand any possible side effects of the additional use of TG01/GM-CSF with gemcitabine - Investigate whether TG01/GM-CSF when given with gemcitabine can produce an immune response - Investigate if the treatment can delay or reduce recurrence of the disease

NCT ID: NCT02250638 Completed - Pancreatic Cancer Clinical Trials

Longitudinal Pancreatic Cancer Study

Start date: May 2014
Phase:
Study type: Observational

To obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of pancreatic cancer.

NCT ID: NCT02246205 Completed - Clinical trials for Malignant Neoplasm of Head of Pancreas

Billroth II or Roux-en-Y Reconstruction for GJ After PD: Randomized Controlled Trial (PAUDA TRIAL)

PAUDA
Start date: February 2013
Phase: N/A
Study type: Interventional

The aim of the study is to compare the effect of Roux-en Y reconstruction (study group, DPCDA) versus classical Child reconstruction (DPCUN) in the incidence of VGL in patients for DPC. The hypotesis of the study is that Roux-en Y reconstruction decreases incidence of DGE after pancreaticoduodenectomy.

NCT ID: NCT02245217 Completed - Pancreatic Cancer Clinical Trials

Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients

Start date: December 12, 2014
Phase: N/A
Study type: Interventional

Study of multi-tracer PET scans to assess response to gemcitabine in pancreatic cancer